Impaired Post Exercise Heart Rate Recovery in Anabolic Steroid Users
Carregando...
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
GEORG THIEME VERLAG KG
Autores
DIAS, R. G.
RONDON, M. U. P. B.
MOREAU, R. L. de Moraes
Citação
INTERNATIONAL JOURNAL OF SPORTS MEDICINE, v.34, n.10, p.931-935, 2013
Resumo
Previous study showed that muscle sympathetic nerve activity (MSNA) was augmented in anabolic steroids users (AASU). In the present study, we tested the hypothesis that the heart rate (HR) responses after maximal exercise testing would be reduced in AASU. 10 male AASU and 10 AAS nonusers (AASNU) were studied. Cardiopulmonary exercise was performed to assess the functional capacity and heart rate recovery. MSNA was recorded directly from the peroneal nerve by microneurography technique. Peak oxygen consumption (VO2) was lower in AASU compared to AASNU (43.66 +/- 2.24 vs. 52.70 +/- 1.68 ml/kg/min, P=0.005). HR recovery (HRR) at first and second minute was lower in AASU than AASNU (21 +/- 2 vs. 27 +/- 2 bpm, P=0.02 and 37 +/- 4 vs. 45 +/- 2 bpm, P=0.05, respectively). MSNA was higher in AASU than AASNU (29 +/- 3 vs. 20 +/- 1 bursts/min, P=0.01). Further analysis showed a correlation between HRR and MSNA (r=- 0.64, P=0.02), HRR at first minute and peak VO2 (r=0.70, P=0.01) and HRR at second minute and peak VO2 (r=0.62, P=0.02). The exacerbated sympathetic outflow associated with a lower parasympathetic activation after maximal exercise, which impairs heart rate recovery, strengthens the idea of autonomic imbalance in AASU.
Palavras-chave
heart rate recovery, functional capacity, anabolic steroids abuse
Referências
- Achar S, 2010, AM J CARDIOL, V106, P893, DOI 10.1016/j.amjcard.2010.05.013
- Aijaz B, 2009, AM J CARDIOL, V103, P1641, DOI 10.1016/j.amjcard.2009.02.013
- Alves MJNN, 2010, MED SCI SPORT EXER, V42, P865, DOI 10.1249/MSS.0b013e3181c07b74
- Balady GJ, 2010, CIRCULATION, V122, P191, DOI 10.1161/CIR.0b013e3181e52e69
- Cole CR, 1999, NEW ENGL J MED, V341, P1351, DOI 10.1056/NEJM199910283411804
- D'Ascenzo S, 2007, TOXICOL LETT, V169, P129, DOI 10.1016/j.toxlet.2006.12.008
- Dikshit BB, 1934, J PHYSIOL-LONDON, V81, P382
- Ebenbichler CF, 2001, ATHEROSCLEROSIS, V158, P483, DOI 10.1016/S0021-9150(01)00465-8
- Fagius J, 1993, Clin Auton Res, V3, P201, DOI 10.1007/BF01826234
- Hao SC, 2002, AM J CARDIOL, V90, P763, DOI 10.1016/S0002-9149(02)02607-3
- Harriss DJ, 2011, INT J SPORTS MED, V32, P819, DOI 10.1055/s-0031-1287829
- Hartgens F, 2003, INT J SPORTS MED, V24, P344
- Laterza MC, 2007, HYPERTENSION, V49, P1298, DOI 10.1161/HYPERTENSIONAHA.106.085548
- Marsh JD, 1998, CIRCULATION, V98, P256
- MCNUTT RA, 1988, AM J CARDIOL, V62, P164, DOI 10.1016/0002-9149(88)91390-2
- Morshedi-Meibodi A, 2002, AM J CARDIOL, V90, P848, DOI 10.1016/S0002-9149(02)02706-6
- NEGRAO CE, 1992, BRAZ J MED BIOL RES, V25, P1045
- Parssinen M, 2002, SPORTS MED, V32, P83, DOI 10.2165/00007256-200232020-00001
- Parssinen M, 2000, INT J SPORTS MED, V21, P225, DOI 10.1055/s-2000-304
- Pereira-Junior PP, 2006, EUR J APPL PHYSIOL, V96, P487, DOI 10.1007/s00421-005-0111-7
- Pouliot WA, 1996, SYNAPSE, V23, P10, DOI 10.1002/(SICI)1098-2396(199605)23:1<10::AID-SYN2>3.0.CO;2-K
- Rocha FL, 2007, AM J PHYSIOL-HEART C, V293, pH3575, DOI 10.1152/ajpheart.01251.2006
- Rosano G M C, 2005, J Endocrinol Invest, V28, P32
- Sader MA, 2001, J AM COLL CARDIOL, V37, P224, DOI 10.1016/S0735-1097(00)01083-4
- Samuels MA, 2007, CIRCULATION, V116, P77, DOI 10.1161/CIRCULATIONAHA.106.678995
- Shetler K, 2001, J AM COLL CARDIOL, V38, P1980, DOI 10.1016/S0735-1097(01)01652-7
- Thiblin I, 2000, J FORENSIC SCI, V45, P16
- WASSERMA.K, 1973, J APPL PHYSIOL, V35, P236
- WASSERMAN K, 1984, AM REV RESPIR DIS, V129, pS35
- Wynne FL, 2003, J ENDOCRINOL INVEST, V26, P181